07:49 AM EDT, 03/25/2026 (MT Newswires) -- C4 Therapeutics ( CCCC ) said Wednesday it dosed the first patient in a phase 1b trial of cemsidomide and dexamethasone in combination with elranatamab to treat relapsed/refractory multiple myeloma, a type of cancer.

The 54-patient study will help establish an optimal dose for cemsidomide in combination with elranatamab by assessing the safety and tolerability, as well as preliminary anti-myeloma activity of the combination.

The company expects phase 1b data in the middle of 2027.

C4 shares were up 2% in premarket activity.